(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
These men carry towers of birds through Mexico's streets. They say their tradition is dying out. - 2The pinch at the pump continues on
- 3Figure out How to Pick a Crematorium: Key Contemplations.
- 4US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- 5People are getting their news from AI – and it’s altering their views
- The 20 Most sultry Style of the Time
- A milestone for Artemis II: Astronauts enter the 'lunar sphere of influence'
- Rescuers again fail to free whale stranded on Germany's Baltic coast
- Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- The Response Uncovered: Disentangling the Secrets of the Universe
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- Figurine of a woman and a goose offers peek at prehistoric beliefs
- Norovirus infections increase significantly, with positive test rates reaching 14%
